Patents Assigned to Academisch Ziekenhuis Maastricht
-
Publication number: 20230228764Abstract: The invention is in the field of molecular diagnosis of medical diseases and their treatment. More in particular, it provides methods and means for detecting hypertension, more in particular essential primary hypertension, even more in particular NOX5-dependent hypertension. The invention also provides methods for the treatment of hypertension, in particular essential primary hypertension, more in particular NOX5-dependent hypertension. The invention also provides theragnostics, wherein therapy is combined with diagnosis, more in particular wherein the level of NOX5 is determined in a sample from a subject and wherein the subject is treated with NOX5 inhibitors or compounds that decrease the levels of NOX5 if the NOX5 levels are above a certain threshold value.Type: ApplicationFiled: May 21, 2021Publication date: July 20, 2023Applicants: Universiteit Maastricht, Academisch Ziekenhuis MaastrichtInventors: Harald Horst Heinz Wilhelm Schmidt, Mahmoud Hassan Mahmoud Elbatrik, Hermann Alois Martin Mucke
-
Publication number: 20230146314Abstract: The invention relates to the radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject. In particular the invention relates to an endorectal probe device for effecting radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject. Furthermore the invention relates to an afterloading apparatus for effecting radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject using an endorectal probe device according to the invention. Moreover the invention relates to a method for effecting radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject, wherein the method implements the endorectal probe device according to the invention.Type: ApplicationFiled: October 17, 2022Publication date: May 11, 2023Applicants: UNiversiteit Maastricht, Academisch Ziekenhuis Maastricht, Stichting Maaastricht Radiation Oncology "Maastro-Clinic"Inventors: Frank VERHAEGEN, Murillo BELLEZZO, Evert VAN LIMBERGEN, Maaike BERBEE, Brigitte RENIERS, Gabriel PAIVA FONSECA
-
Publication number: 20230087609Abstract: The invention relates to a pharmaceutical composition comprising one or more stimulators of soluble guanylate cyclase (sGC), or a combination of at least one stimulator of sGC and at least one activator of sGC, for use in a method of treatment of a disease and/or a disorder that is/are associated with a deficiency of cyclic 3?,5?-guanosine monophosphate in the patient to be treated. The invention also relates to a therapeutic combination comprising a first unit dose comprising an sGC stimulator and a second unit dose comprising an sGC activator. The invention also relates to a therapeutic combination comprising a first unit dose comprising a first sGC stimulator and a second unit dose comprising a second sGC stimulator, for use in a method for the treatment of a disease and/or a disorder that is/are associated with a deficiency of cyclic 3?,5?-guanosine monophosphate in the patient to be treated.Type: ApplicationFiled: February 18, 2021Publication date: March 23, 2023Applicants: Universiteit Maastricht, Academisch Ziekenhuis MaastrichtInventors: Harald Horst Heinz Wilhelm Schmidt, Mahmoud Hassan Mahmoud Elbatrik, Thao-Vi Dao, Ana Isabel Casas Guijarro, Theodora Saridaki, Alexandra Petraina
-
Publication number: 20230083417Abstract: The present invention relates to a therapeutic combination comprising two or three of at least one NADPH oxidase inhibitor, at least one nitric oxide synthase inhibitor and at least one soluble guanylate cyclase agonist. More specifically, the invention relates to said therapeutic combination for use in the prevention or treatment of brain ischemia or for use in the prevention or treatment of ischemia-reperfusion injury. The invention also relates to a pharmaceutical composition comprising two or three of at least one NADPH oxidase inhibitor, at least one nitric oxide synthase inhibitor and at least one soluble guanylate cyclase agonist, and to said pharmaceutical composition for use in the prevention or treatment of brain ischemia or for use in the prevention or treatment of ischemia-reperfusion injury.Type: ApplicationFiled: February 19, 2021Publication date: March 16, 2023Applicants: Universiteit Maastricht, Academisch Ziekenhuis MaastrichtInventors: Harald Horst Heinz Wilhelm Schmidt, Ana Isabel Casas Guijarro
-
Patent number: 11497933Abstract: The invention relates to the radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject. In particular the invention relates to an endorectal probe device for effecting radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject. Furthermore the invention relates to an afterloading apparatus for effecting radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject using an endorectal probe device according to the invention. Moreover the invention relates to a method for effecting radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject, wherein the method implements the endorectal probe device according to the invention.Type: GrantFiled: December 15, 2017Date of Patent: November 15, 2022Assignees: Universiteit Maastricht, Academisch Ziekenhuis Maastricht, Stichting Maastricht Radiation Oncology “Maastro-Clinic”Inventors: Frank Verhaegen, Murillo Bellezzo, Evert Van Limbergen, Maaike Berbee, Brigitte Reniers, Gabriel Paiva Fonseca
-
Patent number: 11487028Abstract: The invention relates to a device for supporting the testing of a brachytherapy applicator prior to the use of the brachytherapy applicator in brachytherapy radiation treatments. The invention also relates to a method for testing of a brachytherapy applicator prior to the use of the brachytherapy applicator in brachytherapy radiation treatments.Type: GrantFiled: March 21, 2018Date of Patent: November 1, 2022Assignees: UNIVERSITET MAASTRICHT, STICHTING MAASTRICHT RADIATION ONCOLOGY “MAASTRO-CLINIC”, ACADEMISCH ZIEKENHUIS MAASTRICHTInventors: Frank Verhaegen, Gabriel Paiva Fonseca, Robert Voncken
-
Patent number: 11480583Abstract: The invention is in the field of molecular diagnosis of medical diseases and their treatment. More in particular, it provides methods and means for detecting hypertension, more in particular essential primary hypertension, even more in particular NOX5-dependent hypertension. The invention also provides methods for the treatment of hypertension, in particular essential primary hypertension, more in particular NOX5-dependent hypertension. The invention also provides theragnostics, wherein therapy is combined with diagnosis, more in particular wherein the level of NOX5 is determined in a sample from a subject and wherein the subject is treated with NOX5 inhibitors or compounds that decrease the levels of NOX5 if the NOX5 levels are above a certain threshold value.Type: GrantFiled: December 16, 2021Date of Patent: October 25, 2022Assignees: Universitet Maastricht, Academisch Ziekenhuis MaastrichtInventors: Harald Horst Heinz Wilhelm Schmidt, Mahmoud Hassan Mahmoud Elbatrik, Hermann Alois Martin Mucke
-
Publication number: 20220128574Abstract: The invention is in the field of molecular diagnosis of medical diseases and their treatment. More in particular, it provides methods and means for detecting hypertension, more in particular essential primary hypertension, even more in particular NOX5-dependent hypertension. The invention also provides methods for the treatment of hypertension, in particular essential primary hypertension, more in particular NOX5-dependent hypertension. The invention also provides theragnostics, wherein therapy is combined with diagnosis, more in particular wherein the level of NOX5 is determined in a sample from a subject and wherein the subject is treated with NOX5 inhibitors or compounds that decrease the levels of NOX5 if the NOX5 levels are above a certain threshold value.Type: ApplicationFiled: December 16, 2021Publication date: April 28, 2022Applicants: Universiteit Maastricht, Academisch Ziekenhuis MaastrichtInventors: Harald Horst Heinz Schmidt, Mahmoud Hassan Mahmoud Elbatrik, Hermann Mucke
-
Patent number: 11112479Abstract: The invention also relates to a MRI apparatus for obtaining images of a target volume of a human and/or animal subject using magnetic resonance imaging (MRI), said MRI apparatus at least comprising: a housing defining a target area for accommodating said human and/or animal subject; at least one main magnet unit and at least one magnetic gradient unit for applying—during use—one or more magnetic field gradients along three independent orthogonal spatial axes in said target area, as well as at least one radiofrequency (RF) pulse generation unit for applying one or more sets of RF pulses towards said target area; a RF receiving unit for acquiring MRI signals possibly having multi-channel spatially sensitive characteristics; and a computer processing unit for processing said acquired MRI signals and for producing said magnetic resonance image data.Type: GrantFiled: October 15, 2018Date of Patent: September 7, 2021Assignees: UNIVERSITEIT MAASTRICHT, ACADEMISCH ZIEKENHUIS MAASTRICHTInventors: Alard Roebroeck, Benedikt Poser, Francisco Lagos Fritz
-
Patent number: 11078544Abstract: This disclosure is in the field of molecular biology and medical diagnosis and provides means and methods for determining the prognosis and disease outcome of a subject having a melanoma. More in particular, this disclosure provides a method for determining whether a subject having a melanoma has a poor prognosis, the method comprising the step of determining in a sample from the subject whether the LY75 promoter is methylated and if the LY75 promoter is methylated, classifying the subject as having a poor prognosis.Type: GrantFiled: March 1, 2019Date of Patent: August 3, 2021Assignees: Universiteit Maastricht, Academisch Ziekenhuis MaastrichtInventors: Manon Van Engeland, Leander Pieter Jo Van Neste, Karin Van Den Hurk
-
Publication number: 20210215716Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of SPON-1 in a sample from the subject, and comparing the amount of SPON-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for the prediction of stroke based on the amount of SPON-1.Type: ApplicationFiled: February 22, 2021Publication date: July 15, 2021Applicants: Roche Diagnostics Operations, Inc., Universiteit Maastricht, Academisch Ziekenhuis MaastrichtInventors: Peter Kastner, Manuel Dietrich, André Ziegler, Ursula-Henrike Wienhues-Thelen, Vinzent Rolny, Ulrich Schotten
-
Publication number: 20210161457Abstract: A method of processing of electrocardiogram includes the steps of providing an electrocardiogram comprising signals in at least two channels; selecting at least two frequency ranges of the signal in each of the said at least two channels; calculating an envelope for the signal in each frequency range in each channel; dividing the calculated envelope of the signal in each frequency range in each channel into QRS complex segment envelopes; and computing an average or median envelope as an average or mean of QRS complex segment envelopes for each frequency range in each channel.Type: ApplicationFiled: November 25, 2020Publication date: June 3, 2021Applicants: Institue of Scientific instruments of the Czech Academy of Sciences, v. v. i., St. Anne's Univeristy Hospital Bmo, Charles University, Universiteit Maastricht, Academisch Ziekenhuis Maastricht, CARDION s.r.o.Inventors: Pavel Jurak, Josef Halamek, Ivo Viscor, Filip Plesinger, Vlastimil Vondra, Radovan Smisek, Pavel Leinveber, Magdalena Matejkova, Jolana Lipoldova, Miroslav Novak, Karol Curila, Jana Vesela, Frits W. Prinzen, Ivo Nekuda, Vit Nekuda
-
Publication number: 20210156875Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of DKK3 in a sample from the subject, and comparing the amount of DKK3 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.Type: ApplicationFiled: January 29, 2021Publication date: May 27, 2021Applicants: Roche Diagnostics Operations, Inc., Universitaet Maastricht, Academisch Ziekenhuis MaastrichtInventors: Johann Karl, Peter Kastner, Roberto Latini, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen, Andre Ziegler, Manuel Dietrich, Jennifer Meessen, Ulrich Schotten
-
Patent number: 10993820Abstract: The invention relates to stents, in particular to a stent for insertion in a vein of a human or animal body. The invention also relates to a catheter stent insertion device for inserting a stent according to the invention in a vein of a human or animal body. The invention also relates to a method for inserting a stent according to the invention in a vein of a human or animal body using a catheter stent insertion device according to the invention.Type: GrantFiled: December 20, 2017Date of Patent: May 4, 2021Assignees: Universiteit Maastricht, Academisch Ziekenhuis MaastrichtInventor: Cornelis Hendrikus Anna Wittens
-
Patent number: 10890584Abstract: A device (100) for detecting an analyte (132) includes a polymer material (112) over a substrate (110); a heat transfer element (114) thermally coupled to the substrate; a temperature modification device (118) thermally coupled to the heat transfer element; a controller (121) to produce a thermal (202) wave emanating from the heat transfer element; a flow cell (122) located and configured to pass a liquid (124) over the polymer material; a temperature sensor (134) to detect a temperature (T2) of the liquid passing over the polymer material; and a processor (123) to calculate a concentration of an analyte (132) in the liquid based at least in part on a phase shift between the thermal wave at the heat transfer element and an attenuated thermal wave (204) in the liquid. Related methods of forming such a device and detecting analytes are also disclosed.Type: GrantFiled: November 3, 2016Date of Patent: January 12, 2021Assignee: Academisch Ziekenhuis MaastrichtInventors: Bart Robert Nicolaas Van Grinsven, Thomas Jan Cleij
-
Patent number: 10617739Abstract: The present invention is in the field of medicine and provides means and methods for the treatment, prevention or amelioration of osteoarthritis. More in particular, it provides a peptide for use in the treatment, amelioration or prevention of osteoarthritis, wherein the peptide is between 12 and 28 amino acids in length and comprises an amino acid sequence according to SEQ ID NO: 16 or a variant thereof according to formula 2, wherein the amino acid sequence of said peptide is comprised in SEQ ID NO: 34 or a variant thereof according to formula 1.Type: GrantFiled: March 31, 2017Date of Patent: April 14, 2020Assignees: Universiteit Maastricht, Academisch Ziekenhuis MaastrichtInventors: Tim Johannes Maria Welting, Marjolein Maria Johanna Caron
-
Patent number: 10383732Abstract: An implant, such as a cranial implant, for attachment to a defect in a bone structure having an edge is described. The implant comprises a direction of extension and a rim extending substantially perpendicular to the direction of extension of the implant. The rim is configured to be attached to the edge of the bone structure and comprises at least one mounting portion configured to accommodate a fastener such that at least a portion of the fastener is extendible in a direction extending away from the rim at an angle which is at most acute with respect to the direction of extension of the implant. The implant is configured such that upon placing the implant in the defect, the fastener is extendible into the edge of the bone defect in a controllable manner.Type: GrantFiled: August 22, 2017Date of Patent: August 20, 2019Assignees: ACADEMISCH ZIEKENHUIS MAASTRICHT, UNIVERSITEIT MAASTRICHTInventors: Maikel Michael Adrianus Beerens, Paul Frans Jozef Laeven, Jules Maria Nikolaas Poukens
-
Patent number: 10324087Abstract: A device for detecting an analyte includes a thermocouple having an assay polymer over a surface of the thermocouple. The assay polymer is formulated to bind to the analyte, and a heat transfer property of the assay polymer varies responsive to an amount of the analyte bound thereto. A method of forming a sensor includes providing an assay polymer over a thermocouple. A method for detecting an analyte includes passing a liquid containing an analyte adjacent a thermocouple having an assay polymer over a surface thereof, binding an analyte to the assay polymer, detecting a temperature of the thermocouple, and calculating a concentration of the analyte in the liquid based at least in part on the heat transfer property of the assay polymer.Type: GrantFiled: April 11, 2016Date of Patent: June 18, 2019Assignees: Universiteit Maastricht, Academisch Ziekenhuis MaastrichtInventors: Bart Robert Nicolaas Van Grinsven, Thomas Jan Cleij
-
Patent number: 10272248Abstract: In some examples, controlling delivery of CRT includes delivering ventricular pacing according to a sequence of different values of at least one of A-V delay or V-V delay, and acquiring one or more electrograms from respective vectors. For each of the different values of the at least one of A-V delay or V-V delay, at least one of a QRS amplitude or a QRS area may be determined based on the one or more electrograms, and a target change in QRS amplitude or QRS area between adjacent ones of the values of the at least one of A-V delay or V-V delay of the sequence may be identified. In response to the identification of the target change, the implantable medical device may deliver the ventricular pacing at a value of the at least one of A-V delay or V-V delay determined based on the identification to provide CRT.Type: GrantFiled: May 31, 2017Date of Patent: April 30, 2019Assignees: Medtronic, Inc., Universiteit Maastricht, Academisch Ziekenhuis MaastrichtInventors: Elien B. Engels, Kevin Vernooy, Alfonso Aranda Hernandez, Frits W. Prinzen, Jeffrey M. Gillberg
-
Patent number: 10260109Abstract: This disclosure is in the field of molecular biology and medical diagnosis and provides means and methods for determining the prognosis and disease outcome of a subject having a melanoma. More in particular, this disclosure provides a method for determining whether a subject having a melanoma has a poor prognosis, the method comprising the step of determining in a sample from the subject whether the LY75 promoter is methylated and if the LY75 promoter is methylated, classifying the subject as having a poor prognosis.Type: GrantFiled: May 26, 2016Date of Patent: April 16, 2019Assignees: Universiteit Maastricht, Academisch Ziekenhuis MaastrichtInventors: Manon Van Engeland, Leander Pieter Jo Van Neste, Karin Van Den Hurk